Litigation Details for Alvotech USA Inc. v. Abbvie Inc (E.D. Va. 2021)

« Back to Dashboard

Alvotech USA Inc. v. Abbvie Inc (E.D. Va. 2021)

Docket		Date Filed	2021-05-11
Court	District Court, E.D. Virginia	Date Terminated	2021-05-12
Cause	28:2201 Declaratory Judgment	Assigned To
Jury Demand	Plaintiff	Referred To
Patents	8,420,081; 8,889,136; 8,926,975; 8,961,973; 9,085,619
Link to Docket	External link to docket

Details for Alvotech USA Inc. v. Abbvie Inc (E.D. Va. 2021)

Date Filed	Document No.	Description	Snippet	Link To Document
2021-05-11				External link to document

Alvotech USA Inc. v. AbbVie Inc., 1:21-cv-00589: Litigation Summary and Patent Analysis

Last updated: October 18, 2026

Alvotech USA Inc. v. AbbVie Inc., No. 1:21-cv-00589-RGA, was a Delaware biosimilar patent dispute involving Alvotech’s proposed adalimumab biosimilar, AVT02, and AbbVie’s Humira franchise. The case ended through a negotiated resolution rather than a trial or final validity ruling. The settlement permitted U.S. commercialization of Alvotech’s adalimumab product beginning July 1, 2023, subject to the settlement terms and regulatory approval.[1][2]

The dispute was commercially important because Humira was AbbVie’s leading product and because Alvotech’s formulation and manufacturing platform was intended to support a high-concentration, citrate-free adalimumab product. The case did not result in a judicial determination that AbbVie’s asserted patents were valid, infringed, or enforceable.

What was Alvotech USA v. AbbVie about?

The case concerned Alvotech’s effort to enter the U.S. market with AVT02, an adalimumab biosimilar referencing AbbVie’s Humira. Alvotech sought judicial relief concerning AbbVie’s patent rights and the ability to launch its product after FDA approval.

AbbVie’s Humira patent estate included patents directed to:

• Adalimumab formulations;
• High-concentration liquid formulations;
• Stabilizers and surfactants;
• Citrate-free formulations;
• Manufacturing and purification processes;
• Methods of treating inflammatory diseases.

The litigation was part of the broader U.S. Humira biosimilar patent campaign that followed the BPCIA process. AbbVie reached separate commercial settlements with multiple biosimilar developers, including agreements that delayed U.S. launches until dates in 2023.

Case identification

Item	Detail
Case	Alvotech USA Inc. v. AbbVie Inc.
Civil action	No. 1:21-cv-00589-RGA
Court	U.S. District Court for the District of Delaware
Filing year	2021
Plaintiff	Alvotech USA Inc.
Defendant	AbbVie Inc.
Reference product	Humira, adalimumab
Proposed biosimilar	AVT02
U.S. commercial partner	Teva Pharmaceuticals
Resolution	Settlement and dismissal
Agreed U.S. launch date	July 1, 2023

What patents protected Humira against Alvotech?

AbbVie’s relevant patent portfolio was concentrated in late-expiring formulation and manufacturing patents rather than the original composition-of-matter protection for adalimumab.

Publicly identified Humira-related patents include the following examples:

Patent	General subject matter	Strategic relevance
U.S. Patent No. 10,688,069	Adalimumab formulation technology	Potential barrier to high-concentration or stable liquid products
U.S. Patent No. 10,702,563	Adalimumab formulation-related technology	Relevant to formulation design and patent-dance disputes
U.S. Patent No. 10,695,414	Humira-related formulation or process claims	Part of AbbVie’s extended patent strategy
U.S. Patent No. 10,105,380	Adalimumab-related formulation technology	Example of the later-generation patent estate

The precise patents asserted against a particular biosimilar depend on the product’s formulation, concentration, excipients, manufacturing process, and the disclosures exchanged under the BPCIA. A patent’s presence in the broader Humira estate does not establish that it was asserted against AVT02 in this action.

The central commercial issue was whether Alvotech could launch a formulation and manufacturing process without infringing enforceable AbbVie claims, or whether it would need to litigate through trial and appeal before entering the market.

Did the case involve a Paragraph IV challenge?

No. The case did not proceed as a conventional Hatch-Waxman Paragraph IV case.

Adalimumab is a biologic, so the relevant statutory framework was the Biologics Price Competition and Innovation Act. The BPCIA establishes the biosimilar application process, patent-information exchange, and potential infringement litigation. FDA-listed biologics appear in the Purple Book, not the Orange Book.[3]

The distinction matters:

Issue	Small-molecule generic	Adalimumab biosimilar
Primary statute	Hatch-Waxman Act	BPCIA
Application	ANDA	351(k) biosimilar application
Patent listing source	Orange Book	Purple Book and BPCIA exchanges
Challenge terminology	Paragraph IV certification	BPCIA patent-dance litigation
Reference product	Listed drug	Licensed biologic
Exclusivity framework	New chemical entity and related periods	Reference-product and biosimilar exclusivity rules

Alvotech’s dispute with AbbVie was therefore a biosimilar patent litigation matter, not an Orange Book Paragraph IV action.

What was the litigation timeline?

Date	Event
2021	Alvotech initiated the Delaware action involving its proposed adalimumab biosimilar
2021-2022	The parties litigated patent and launch issues under the BPCIA framework
September 2022	Alvotech, Teva and AbbVie announced a U.S. settlement covering the adalimumab product
October 2022	The Delaware action was resolved through dismissal following settlement-related filings
July 1, 2023	Contractual U.S. launch date for Alvotech’s adalimumab product
July 2023	FDA approved Simlandi, the U.S. product marketed by Teva and supplied through Alvotech’s platform

The settlement removed the need for the court to decide claim construction, infringement, validity, enforceability, or an injunction. No reported final judgment invalidated the relevant AbbVie patents.

How did the settlement affect generic or biosimilar entry?

The settlement created a defined entry date instead of allowing immediate launch after FDA approval. The agreement permitted Alvotech and Teva to commercialize the product in the United States beginning July 1, 2023.[1]

This type of settlement gives the reference-product sponsor a controlled period of continued market protection while giving the biosimilar developer a predictable launch date. It also reduces the risk that litigation, injunction proceedings, or an appellate reversal will disrupt commercial planning.

The agreement did not mean that AbbVie’s entire Humira patent estate was invalid or unenforceable. It resolved the parties’ dispute on contractual terms. The commercial result was delayed entry, not a merits-based patent victory for either side.

What did the settlement not establish?

The settlement did not establish:

• That AVT02 infringed an AbbVie patent;
• That AbbVie’s asserted patents were valid;
• That the patents were unenforceable;
• That all Humira patents were exhausted;
• That Alvotech could freely launch outside the agreed settlement parameters;
• That other biosimilar developers received identical rights.

Settlement terms are product-specific and party-specific. A separate biosimilar developer cannot automatically rely on Alvotech’s resolution as a defense to AbbVie’s patent claims.

What was the FDA status of Alvotech’s adalimumab product?

The FDA approved Simlandi, adalimumab-ryvk, in July 2023. The product was developed by Alvotech and commercialized in the United States through Teva.[4]

Simlandi was approved as a biosimilar to Humira. It later received an interchangeable designation, allowing substitution at the pharmacy level subject to state law and applicable prescribing rules. The product is a high-concentration, citrate-free adalimumab formulation designed to compete with newer Humira presentations rather than only the original low-concentration product.

FDA approval did not itself eliminate patent risk. The regulatory approval and the patent settlement were separate components of the launch pathway.

How strong was AbbVie’s patent estate against Alvotech?

AbbVie’s patent position was commercially strong but legally untested in this case.

Its strengths included:

1. A large portfolio extending beyond the original molecule patent.
2. Formulation patents aligned with the commercial characteristics of newer Humira products.
3. Multiple patent families that could increase litigation cost and timing risk.
4. The ability to negotiate launch dates with biosimilar developers before trial.
5. Product-specific claims that could target high-concentration and citrate-free formulations.

Its limitations included:

1. The absence of a merits judgment in the Alvotech case.
2. Potential validity and obviousness challenges against later-filed formulation claims.
3. The possibility that biosimilar developers could design around particular formulation limitations.
4. The need to prove infringement for the specific product and manufacturing process.
5. Reduced practical protection after multiple biosimilar settlements established 2023 entry dates.

The patent estate was therefore effective as a settlement and launch-management tool, but the Alvotech docket does not provide a judicial ruling confirming the full strength of the asserted claims.

What formulation patents affected Alvotech’s product?

Alvotech’s AVT02 program was directed to a high-concentration, citrate-free adalimumab formulation. Those characteristics were commercially significant because they corresponded to the newer Humira presentation that had gained substantial prescribing and sales share.

Formulation patent risk generally turns on:

• Adalimumab concentration;
• Buffer selection;
• Presence or absence of citrate;
• Surfactant identity and concentration;
• Stabilizing excipients;
• pH range;
• Protein aggregation limits;
• Container and delivery device;
• Manufacturing and purification steps.

A biosimilar may avoid one claim by changing an excipient or process, but the change can affect stability, injection tolerability, device compatibility, or FDA comparability. Formulation patents therefore can create practical barriers even where the active ingredient itself is no longer covered by composition-of-matter protection.

Did the case create biosimilar or manufacturing barriers?

Yes. The dispute illustrates two separate barriers to entry.

Patent barrier

AbbVie’s formulation and process patents could delay launch or force a settlement. The risk was not limited to the active ingredient. High-concentration and citrate-free products may implicate later patent families that expire years after the original Humira molecule protection.

Manufacturing barrier

Alvotech’s commercial position depended on its ability to manufacture AVT02 consistently at commercial scale. Biosimilar approval requires extensive analytical, pharmacokinetic, immunogenicity, and manufacturing data. A formulation that is technically different from Humira may still qualify as biosimilar, but the sponsor must demonstrate that the differences do not produce clinically meaningful effects.

The settlement addressed the patent barrier. It did not remove the technical, regulatory, supply-chain, or manufacturing requirements for commercialization.

How did Alvotech compare with competing Humira biosimilar developers?

Alvotech entered a crowded U.S. market that included Amgen, Boehringer Ingelheim, Sandoz, Celltrion, Organon, Pfizer, Samsung Bioepis and others. Most major developers negotiated launch arrangements with AbbVie.

Company	Product	General U.S. entry position
Amgen	Amjevita, adalimumab-atto	January 2023
Boehringer Ingelheim	Cyltezo, adalimumab-adbm	July 2023
Organon/Samsung Bioepis	Hadlima, adalimumab-bwwd	July 2023
Sandoz	Hyrimoz, adalimumab-adaz	September 2023
Celltrion	Yuflyma, adalimumab-aaty	2023
Teva/Alvotech	Simlandi, adalimumab-ryvk	July 2023

Alvotech’s competitive differentiation was its high-concentration, citrate-free product and its manufacturing relationship with Teva. Its commercial exposure depended on gaining formulary access in a market where AbbVie had already converted a significant portion of demand to higher-concentration Humira presentations and where several biosimilars entered within months of one another.

What revenue exposure did the litigation create?

Humira generated tens of billions of dollars in annual global revenue before biosimilar entry. AbbVie reported Humira sales of approximately $21.2 billion in 2022, before the full impact of U.S. biosimilar competition.[5]

For AbbVie, the Alvotech dispute was part of a broader erosion of U.S. Humira exclusivity. For Alvotech and Teva, the settlement provided a defined opportunity to capture share but also compressed the period in which a single biosimilar could establish preferred formulary status.

The economic effect depended on:

• Launch timing;
• Wholesale acquisition price;
• Rebates and payer contracting;
• Interchangeability;
• Pharmacy substitution;
• Supply reliability;
• Physician adoption;
• The number of competing adalimumab products.

What is the current litigation status?

The Delaware action was resolved and dismissed following the settlement. There was no publicly reported trial verdict or final appellate ruling addressing the validity or infringement of AbbVie’s patents against Alvotech’s product.

The practical litigation status is therefore closed, while the commercial consequences continue through the competitive U.S. adalimumab market.

Key Takeaways

• Alvotech USA v. AbbVie, No. 1:21-cv-00589-RGA, involved Alvotech’s AVT02 adalimumab biosimilar.
• The case was governed by the BPCIA, not the Hatch-Waxman Paragraph IV process.
• AbbVie relied on a broad Humira patent estate, including later-expiring formulation and process patents.
• The parties settled in 2022, avoiding a merits ruling.
• The settlement permitted U.S. launch on July 1, 2023.
• Teva commercialized the FDA-approved product Simlandi, adalimumab-ryvk.
• The case did not invalidate AbbVie patents or establish noninfringement.
• Patent risk shifted from molecule protection to formulation, manufacturing and device-related claims.
• The commercial impact was reduced by simultaneous or near-simultaneous entry from multiple adalimumab biosimilars.

FAQs About Alvotech v. AbbVie

Did Alvotech win its patent case against AbbVie?

No merits victory was entered. The dispute ended through settlement and dismissal, so the court did not determine whether AbbVie’s patents were valid, infringed, or enforceable.

When could Alvotech launch its Humira biosimilar in the United States?

The settlement permitted U.S. commercial launch beginning July 1, 2023, subject to FDA approval and the agreement’s terms.

Was Simlandi covered by an Orange Book patent listing?

No. Simlandi is a biologic biosimilar. Its patent dispute was handled under the BPCIA framework, and biologics are tracked through FDA’s Purple Book rather than the Orange Book.

Does the Alvotech settlement affect other Humira biosimilars?

No. The settlement governed the parties and product covered by that agreement. Other biosimilar sponsors remained subject to their own patent settlements, licenses and litigation outcomes.

Did AbbVie retain patent protection after the Alvotech settlement?

Yes. The settlement resolved Alvotech’s dispute but did not cancel AbbVie’s Humira patent portfolio or create a general invalidity ruling against AbbVie’s patents.

References

1. Alvotech. (2022, September 27). Alvotech and Teva announce settlement with AbbVie related to AVT02 in the United States. Company press release.
2. U.S. District Court for the District of Delaware. (2021-2022). Alvotech USA Inc. v. AbbVie Inc., No. 1:21-cv-00589-RGA. PACER docket materials.
3. U.S. Food and Drug Administration. (n.d.). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov/
4. U.S. Food and Drug Administration. (2023, July). Simlandi (adalimumab-ryvk) prescribing information and approval materials.
5. AbbVie Inc. (2023). 2022 annual report.